AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Checkmate 9la asco 202112/7/2023 ![]() ![]() However, for never smoker female patients, Pem + chemo is preferable to choose for demonstrating favorable OS benefit than N-I + chemo. As for safety profiles, N-I + chemo showed no significant difference relative to Pem + chemo in any grade adverse events: (RR 1.03, 95% CI 0.99-1.10), but demonstrated reduced toxicity in chemo-related adverse events, such as anemia (RR 0.63, 95% CI 0.49-0.81), neutropenia (RR0.51, 95% CI 0.33-0.79), and thrombocytopenia (RR 0.38, 95% CI 0.21-0.69).Ĭonclusions: N-I + chemo is a promising treatment option for providing comparable OS related to Pem + chemo. The ITC results suggested that N-I + chemo is comparable to Pem + chemo in OS (HR 1.03, 95% CI 0.82-1.30) and ORR (RR 0.81, 95% CI 0.62-1.06), but tended to yield inferior PFS (HR 1.28, 95% CI 1.04-1.59) than did Pem + chemo. Results: Four eligible randomized trials (CheckMate9LA, KEYNOTE-021G, KEYNOTE 189, KEYNOTE 407) involving 2017 patients were available to analyze. Subgroup analyses were stratified according to PD-L1 expression and clinical characteristics. A well-accepted adjusted indirect treatment comparison (ITC) approach was selected to pool efficacy results and safety outcomes. Methods: Relevant databases were searched for eligible trials. We conducted this indirect comparison to compare the efficacy of and safety between these two treatments for providing reference for decision making. 3Centre for Translational Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Chinaīackground: Nivolumab + ipilimumab + two cycles chemotherapy (N-I + chemo, intensive immunotherapy but chemo-light) and pembrolizumab + chemotherapy (Pem + chemo) were both recommended as first-line treatment for metastatic non-small cell lung carcinoma (NSCLC) patients.2Key Laboratory of Environment and Genes Related to Diseases, Xi’an Jiaotong University, Ministry of Education of China, Xi’an, China. ![]() 1Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China.Panpan Jiang 1† Ziyang Mao 1† Qinyang Wang 1 Xiaohui Jia 1 Luying Geng 1 Hong Xu 1 Lili Jiang 1 Chengcheng Yang 1 Min Jiao 1 Hui Guo 1,2,3*
0 Comments
Read More
Leave a Reply. |